As previously reported last night, Guggenheim initiated coverage of Entrada Therapeutics (TRDA) with a Buy rating and $20 price target The ENTR-601 series is being rapidly advanced to potentially access the roughly $1.4Bn Duchenne Muscular Dystrophy addressable market, represented by exon 44, 45, 50, and 51 skipping, the analyst tells investors. Given the cadence of platform validating data, the firm believes the stock could trade more than two times higher relative to current levels exiting 2026, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics initiated with a Buy at Guggenheim
- Entrada Therapeutics initiated with an Outperform at Oppenheimer
- Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
- Entrada Therapeutics highlights RNA pipeline progress and outlook
- Entrada Therapeutics reports progress across development portfolio